Literature DB >> 7051243

Antibacterial therapy for acute otitis media: a critical analysis.

C Marchant, P A Shurin.   

Abstract

Twenty-five published trials of antibacterial therapy for acute otitis media were reviewed according to 13 methodologic standards for the design of clinical trials. Randomized, controlled trials, often with the double-blind technique, have been widely applied to assess efficacy. Bias can be further avoided by prognostic stratification according to known risk factors and by the measurement and analysis of patient compliance with treatment. A less frequently recognized problem is the insensitive trial. Bacteriologic diagnosis of the middle ear exudate before therapy can improve the sensitivity of clinical trials. The eradication of pathogens from the middle ear may be a more sensitive measure of outcome than the reduction of ear effusion. The analysis of type II statistical error should be included in trials that reveal no difference between antibacterial agents. The evaluation of new antibacterial agents for this important health problem requires rigorous research design.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7051243     DOI: 10.1093/clinids/4.2.506

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  3 in total

Review 1.  Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequences for therapy.

Authors:  R de Groot; G Dzoljic-Danilovic; B van Klingeren; W H Goessens; H J Neyens
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

2.  Cefetamet pivoxil vs cefaclor in the treatment of acute otitis media in children.

Authors:  S Furman; L Berkowicz; J Dippenaar; D A Hellenberg; M S Montanus; A Steinberg; R Schall
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 3.  Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media.

Authors:  D A Kafetzis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-10       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.